Quick Takeaways
- Erik Harris has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $2,581,622.
- Recent insider filing activity is available below.
Follow Filing Activity
Follow Erik Harris and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc. | EVP & Chief Commercial Officer | $2,040,942 | -$240,289 | -11% | 01 Mar 2026 |
| DNLI | Denali Therapeutics Inc. | Director | $347,690 | 31 May 2024 | ||
| RZLT | Rezolute, Inc. | Director | $192,990 | 19 Nov 2025 | ||
| INZY | Inozyme Pharma, Inc. | Director | 03 Oct 2024 |
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|